DirectFast™ SARS-CoV-2 multiplex assay, ​a probe-based real-time RT-PCR kit, is designed for 'DIRECT' and 'FAST' detection of SARS-CoV-2 RNA. Crude RNA samples prepared by a lysis buffer (NAExDB) or heating, as well as purified RNA, could be used as templates for this assay kit without compromising sensitivity and accuracy. Using this fast kit, a reaction can quickly complete real-time RT-PCR cycles within one hour (45-50 mins for 40 cycles). The multiple target detection (ORF8, N, S genes of SARS-CoV-2) lowers the risk of false-negative results induced by mutations of viral RNA. Additionally, this assay installs a heat-labile UNG (uracil-N-glycosylase) and dUTP system to prevent carryover contamination.

 

Fig. Sensitive detection of SARS-CoV-2 with DirectFast™ SARS-CoV-2 Multiplex assay. SARS-CoV-2 viral RNAs were spiked into the nasopharyngeal swab collections (in UTM) at a concentration of 106 ~ 101 copies/μL. RNAs were prepared from each spiked sample according to this product's IFU. Each 3μL of the purified viral RNA was used for SARS-CoV-2 detection as a template. The reactions were performed on a real-time PCR instrument, the Bio-Rad CFX96.

Application 

• Direct real-time detection of SARS-CoV-2 

Quality control

• Functional analysis
• DirectFast™ SARS-CoV-2 multiplex assay is evaluated by real-time RT-PCR using the 10-fold serial-diluted purified SARS-CoV-2 RNA and PC(SCV2) with target-specific primers and hydrolysis probes according to the protocol supplied.

본 제품 관련 자료는 sale@nanohelix.net 로 문의주시기 바랍니다. 

감사합니다.